162 related articles for article (PubMed ID: 10552989)
1. In-vitro activity of voriconazole (UK-109,496), LY303366 and other antifungal agents against oral Candida spp. isolates from HIV-infected patients.
Chávez M; Bernal S; Valverde A; Gutierrez MJ; Quindós G; Mazuelos EM
J Antimicrob Chemother; 1999 Nov; 44(5):697-700. PubMed ID: 10552989
[TBL] [Abstract][Full Text] [Related]
2. In vitro activity of voriconazole, itraconazole, caspofungin, anidulafungin (VER002, LY303366) and amphotericin B against aspergillus spp.
Serrano Mdel C; Valverde-Conde A; Chávez M M; Bernal S; Claro RM; Pemán J; Ramirez M; Martín-Mazuelos E
Diagn Microbiol Infect Dis; 2003 Feb; 45(2):131-5. PubMed ID: 12614985
[TBL] [Abstract][Full Text] [Related]
3. Susceptibility of fluconazole-resistant clinical isolates of Candida spp. to echinocandin LY303366, itraconazole and amphotericin B.
Cuenca-Estrella M; Mellado E; Díaz-Guerra TM; Monzón A; Rodríguez-Tudela JL
J Antimicrob Chemother; 2000 Sep; 46(3):475-7. PubMed ID: 10980178
[TBL] [Abstract][Full Text] [Related]
4. In vitro susceptibilities of Candida dubliniensis isolates tested against the new triazole and echinocandin antifungal agents.
Pfaller MA; Messer SA; Gee S; Joly S; Pujol C; Sullivan DJ; Coleman DC; Soll DR
J Clin Microbiol; 1999 Mar; 37(3):870-2. PubMed ID: 9986880
[TBL] [Abstract][Full Text] [Related]
5. National surveillance of species distribution in blood isolates of Candida species in Japan and their susceptibility to six antifungal agents including voriconazole and micafungin.
Takakura S; Fujihara N; Saito T; Kudo T; Iinuma Y; Ichiyama S
J Antimicrob Chemother; 2004 Feb; 53(2):283-9. PubMed ID: 14688039
[TBL] [Abstract][Full Text] [Related]
6. In vitro activity of three new triazoles and one echinocandin against Candida bloodstream isolates from cancer patients.
Laverdiere M; Hoban D; Restieri C; Habel F
J Antimicrob Chemother; 2002 Jul; 50(1):119-23. PubMed ID: 12096017
[TBL] [Abstract][Full Text] [Related]
7. In vitro activities of voriconazole (UK-109,496) and four other antifungal agents against 394 clinical isolates of Candida spp.
Marco F; Pfaller MA; Messer S; Jones RN
Antimicrob Agents Chemother; 1998 Jan; 42(1):161-3. PubMed ID: 9449278
[TBL] [Abstract][Full Text] [Related]
8. Trends in frequency and in vitro susceptibilities to antifungal agents, including voriconazole and anidulafungin, of Candida bloodstream isolates. Results from a six-year study (1996-2001).
Marco F; Danés C; Almela M; Jurado A; Mensa J; de la Bellacasa JP; Espasa M; Martínez JA; Jiménez de Anta MT
Diagn Microbiol Infect Dis; 2003 Aug; 46(4):259-64. PubMed ID: 12944017
[TBL] [Abstract][Full Text] [Related]
9. Activity of MK-0991 (L-743,872), a new echinocandin, compared with those of LY303366 and four other antifungal agents tested against blood stream isolates of Candida spp.
Marco F; Pfaller MA; Messer SA; Jones RN
Diagn Microbiol Infect Dis; 1998 Sep; 32(1):33-7. PubMed ID: 9791755
[TBL] [Abstract][Full Text] [Related]
10. [In vitro activity of fluconazole, voriconazole and posaconazole against Candida spp].
Rubio Calvo MC; Gil J; Ramírez de Ocáriz I; Benito R; Rezusta A
Rev Esp Quimioter; 2003 Jun; 16(2):227-32. PubMed ID: 12973462
[TBL] [Abstract][Full Text] [Related]
11. In vitro activities of ravuconazole and voriconazole compared with those of four approved systemic antifungal agents against 6,970 clinical isolates of Candida spp.
Pfaller MA; Messer SA; Hollis RJ; Jones RN; Diekema DJ
Antimicrob Agents Chemother; 2002 Jun; 46(6):1723-7. PubMed ID: 12019081
[TBL] [Abstract][Full Text] [Related]
12. Antifungal activity of the echinocandin anidulafungin (VER002, LY-303366) against yeast pathogens: a comparative study with M27-A microdilution method.
Arévalo MP; Carrillo-Muñoz AJ; Salgado J; Cardenes D; Brió S; Quindós G; Espinel-Ingroff A
J Antimicrob Chemother; 2003 Jan; 51(1):163-6. PubMed ID: 12493803
[TBL] [Abstract][Full Text] [Related]
13. In vitro activity of voriconazole against Mexican oral yeast isolates.
Sánchez Vargas LO; Eraso E; Carrillo-Muñoz AJ; Aguirre JM; Gaitán-Cepeda LA; Quindós G
Mycoses; 2010 May; 53(3):200-3. PubMed ID: 19389066
[TBL] [Abstract][Full Text] [Related]
14. In vitro antifungal activities of anidulafungin and micafungin, licensed agents and the investigational triazole posaconazole as determined by NCCLS methods for 12,052 fungal isolates: review of the literature.
Espinel-Ingroff A
Rev Iberoam Micol; 2003 Dec; 20(4):121-36. PubMed ID: 15456349
[TBL] [Abstract][Full Text] [Related]
15. In vitro susceptibility testing of Candida and Aspergillus spp. to voriconazole and other antifungal agents using Etest: results of a French multicentre study.
Mallié M; Bastide JM; Blancard A; Bonnin A; Bretagne S; Cambon M; Chandenier J; Chauveau V; Couprie B; Datry A; Feuilhade M; Grillot R; Guiguen C; Lavarde V; Letscher V; Linas MD; Michel A; Morin O; Paugam A; Piens MA; Raberin H; Tissot E; Toubas D; Wade A
Int J Antimicrob Agents; 2005 Apr; 25(4):321-8. PubMed ID: 15784312
[TBL] [Abstract][Full Text] [Related]
16. In vitro susceptibilities of clinical yeast isolates to a new echinocandin derivative, LY303366, and other antifungal agents.
Pfaller MA; Messer SA; Coffman S
Antimicrob Agents Chemother; 1997 Apr; 41(4):763-6. PubMed ID: 9087485
[TBL] [Abstract][Full Text] [Related]
17. In vitro activity of a new echinocandin, LY303366, and comparison with fluconazole, flucytosine and amphotericin B against Candida species.
Moore CB; Oakley KL; Denning DW
Clin Microbiol Infect; 2001 Jan; 7(1):11-6. PubMed ID: 11284937
[TBL] [Abstract][Full Text] [Related]
18. In vitro synergy testing of anidulafungin with itraconazole, voriconazole, and amphotericin B against Aspergillus spp. and Fusarium spp.
Philip A; Odabasi Z; Rodriguez J; Paetznick VL; Chen E; Rex JH; Ostrosky-Zeichner L
Antimicrob Agents Chemother; 2005 Aug; 49(8):3572-4. PubMed ID: 16048988
[TBL] [Abstract][Full Text] [Related]
19. Oral Candida isolates among HIV-infected subjects in Nigeria.
Nweze EI; Ogbonnaya UL
J Microbiol Immunol Infect; 2011 Jun; 44(3):172-7. PubMed ID: 21524610
[TBL] [Abstract][Full Text] [Related]
20. In vitro pharmacodynamic characteristics of amphotericin B, caspofungin, fluconazole, and voriconazole against bloodstream isolates of infrequent Candida species from patients with hematologic malignancies.
Di Bonaventura G; Spedicato I; Picciani C; D'Antonio D; Piccolomini R
Antimicrob Agents Chemother; 2004 Nov; 48(11):4453-6. PubMed ID: 15504881
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
